Drugs / EPCs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06359912 | Apr 2024 → Apr 2025 | limb ischemia | Allife Medical Science and Technology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EPCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06359912 ↗ |
| Modality | Cell therapy | “transplantation of allogeneic Endothelial Progenitor Cells” NCT06359912 ↗ |
| Route | Intravenous | “EPCs intravenous infusion” NCT06359912 ↗ |